Provided by Tiger Fintech (Singapore) Pte. Ltd.

Karyopharm Therapeutics

5.29
+0.34006.87%
Volume:70.26K
Turnover:375.25K
Market Cap:44.52M
PE:-0.38
High:5.50
Open:4.94
Low:4.94
Close:4.95
Loading ...

RBC Lowers Price Target on Karyopharm Therapeutics to $43 From $45, Keeps Outperform Rating

MT Newswires Live
·
03 Apr

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
02 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Karyopharm Therapeutics (KPTI) Receives a Buy from Piper Sandler

TIPRANKS
·
19 Mar

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
04 Mar

Karyopharm Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
03 Mar

Karyopharm Therapeutics Inc : Baird Cuts Target Price to $54 From $75

THOMSON REUTERS
·
28 Feb

Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
26 Feb

Karyopharm Therapeutics Inc : H.c. Wainwright Adjusts Target Price to $56 From $7 to Reflect 1-for-15 Reverse Stock Split

THOMSON REUTERS
·
26 Feb

Karyopharm trading halted, news pending

TIPRANKS
·
26 Feb

Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split

MT Newswires Live
·
25 Feb

Karyopharm Announces 1-for-15 Reverse Stock Split

THOMSON REUTERS
·
24 Feb

Karyopharm Announces 1-for-15 Reverse Stock Split

PR Newswire
·
24 Feb

Karyopharm Therapeutics: Hold Rating Maintained Amid Revenue Stagnation and Competitive Pressures

TIPRANKS
·
23 Feb

Karyopharm Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Feb

Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating

TIPRANKS
·
20 Feb

Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
20 Feb

Barclays Sticks to Its Buy Rating for Karyopharm Therapeutics (KPTI)

TIPRANKS
·
20 Feb

Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ...

GuruFocus.com
·
20 Feb

Q4 2024 Karyopharm Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
20 Feb